PUBBLICAZIONI 2015
Barcellini W., Fattizzo B.
Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia.
DIS MARKERS 2015; 2015(): 635670-635670.
_______________________________________
Barcellini W.
New Insights in the Pathogenesis of Autoimmune Hemolytic Anemia.
TRANSFUS MED HEMOTH 2015; 42(5): 287-293.
________________________________________
King M.J., Garcon L., Hoyer J.D., Iolascon A., Picard V., Stewart G., Bianchi P., Lee S.H., Zanella A., International Council for Standardization in Haematology.
ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders.
INT J LAB HEMATOL 2015; 37(3): 304-325.
________________________________________
Barcellini W.
Pitfalls in the diagnosis of autoimmune haemolytic anaemia.
BLOOD TRANSFUS 2015; 13(1): 3-5.
________________________________________
Barcellini W.
Current treatment strategies in autoimmune hemolytic disorders.
EXPERT REV HEMATOL 2015; 8(5): 681-691.
________________________________________
Barcellini W.
Immune Hemolysis: Diagnosis and Treatment Recommendations.
SEMIN HEMATOL 2015; 52(4): 304-312.
Raggiungi il documento (DOI®)
________________________________________
Grace R.F., Zanella A., Neufeld E.J., Morton D.H., Eber S., Yaish H., Glader B.
Erythrocyte pyruvate kinase deficiency: 2015 status report.
AM J HEMATOL 2015; 90(9): 825-830.
________________________________________
Tedeschi A., Picardi P., Ferrero S., Benevolo G., Margiotta Casaluci G., Varettoni M., Baratè C., Motta M., Gini G., Goldaniga M., Visco C., Zaja F., Belsito Petrizi V., Ravelli E., Gentile M., Urbano M.A., Franceschetti S., Ghione P., Orsucci L., Frustaci A.M., Gaidano G., Vitolo U., Morra E.
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.
LEUK LYMPHOMA 2015; 56(9): 2637-2642.
________________________________________
Tadmor T., Bari A., Marcheselli L., Sacchi S., Aviv A., Baldini L., Gobbi P.G., Pozzi S., Ferri P., Cox M.C., Cascavilla N., Iannitto E., Federico M., Polliack A.
Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.
MAYO CLIN PROC 2015; 90(6): 756-764.
________________________________________
Arribas A.J., Rinaldi A., Mensah A.A., Kwee I., Cascione L., Robles E.F., Martinez-Climent J.A., Oscier D., Arcaini L., Baldini L., Marasca R., Thieblemont C., Briere J., Forconi F., Zamò A., Bonifacio M., Mollejo M., Facchetti F., Dirnhofer S., Ponzoni M., Bhagat G., Piris M.A., Gaidano G., Zucca E., Rossi D. , Bertoni F.
DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.
BLOOD 2015; 125(12): 1922-1931.
________________________________________
Cozzani E., Iurlo A., Merlo G., Cattaneo D., Burlando M., Pierri I., Gugliotta G., Parodi A.
Essential Thrombocythemia: The Dermatologic Point of View.
CL LYMPH MYELOM LEUK 2015; 15(12): 739-747.
________________________________________
Boiocchi L., Gianelli U., Iurlo A., Fend F., Bonzheim I., Cattaneo D., Knowles D.M., Orazi A.
Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications.
MODERN PATHOL 2015; 28(11): 1448-1457.
________________________________________
Mori S., Vagge E., le Coutre P., Abruzzese E., Martino B., Pungolino E., Elena C., Pierri I., Assouline S., D’Emilio A., Gozzini A., Giraldo P., Stagno F., Iurlo A., Luciani M., De Riso G., Redaelli S., Kim D.W., Pirola A., Mezzatesta C., Petroccione A., Lodolo D’Oria A., Crivori P., Piazza R., Gambacorti-Passerini C.
Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.
AM J HEMATOL 2015; 90(10): 910-914.
________________________________________
Breccia M., Efficace F., Sica S., Abruzzese E., Cedrone M., Turri D., Gobbi M., Carella A.M., Gozzini A., Usala E., Cavazzini F., Danise P., Tiribelli M. , Binotto G., Pregno P., Bocchia M. , Gaidano G., Crugnola M., Bonifacio M., Avanzini P., Celesti F., Guella A., Martino B., Annunziata M., Luciano L., Stagno F., Vallisa D., Pungolino E., Iurlo A., Rambaldi A., Nardiello I., Orlandi E., Gambacorti-Passerini C., Alimena G.
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.
LEUKEMIA RES 2015; 39(10): 1055-1059.
________________________________________
Cascavilla N., De Stefano V., Pane F. , Pancrazzi A., Iurlo A., Gobbi M., Palandri F. , Specchia G., Liberati A.M., D’adda M., Gaidano G., Fjerza R., Achenbach H., Smith J., Wilde P., Vannucchi A.M.
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.
DRUG DES DEV THER 2015; 9(): 2687-2694.
________________________________________
Anania M.C., Gasparri F., Cetti E., Fraietta I., Todoerti K., Miranda C., Mazzoni M., Re C., Colombo R., Ukmar G., Camisasca S., Pagliardini S., Pierotti M.A., Neri A., Galvani A., Greco A.
Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening.
ONCOTARGET 2015; 6(33): 34629-34648.
________________________________________
Colombo M. , *Galletti S., Garavelli S., Platonova N., Paoli A., Basile A., Taiana E., Neri A., Chiaramonte R.
Notch signaling deregulation in multiple myeloma: A rational molecular target.
ONCOTARGET 2015; 6(29): 26826-26840.
________________________________________
Lionetti M., Barbieri M., Todoerti K., Agnelli L., Fabris S., Tonon G., Segalla S., Cifola I., Pinatel E., Tassone P., Musto P., Baldini L., Neri A.
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.
ONCOTARGET 2015; 6(28): 26129-26141.
________________________________________
Simeon V., Todoerti K., Rocca F.L., Caivano A., Trino S., Lionetti M., Agnelli L., De Luca L., Laurenzana I., Neri A., Musto P.
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.
INT J MOL SCI 2015; 16(8): 17514-17534.
________________________________________
Chiaramonte R., Colombo M. , Bulfamante G., Falleni M., Tosi D., Garavelli S., De Simone D., Vigolo E., Todoerti K., Neri A., Platonova N.
Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1a chemokine system.
INT J BIOCHEM CELL B 2015; 66(): 134-140.
________________________________________
Lionetti M., Barbieri M., Todoerti K., Agnelli L., Marzorati S., Fabris S., Ciceri G., *Galletti S., Milesi G., Manzoni M., Mazzoni M., Greco A., Tonon G., Musto P., Baldini L., Neri A.
Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
ONCOTARGET 2015; 6(27): 24205-24217.
________________________________________
Di Martino M.T., Guzzi P.H., Caracciolo D., Agnelli L., Neri A., Walker BA., Morgan GJ., Cannataro M., Tassone P., Tagliaferri P.
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma.
ONCOTARGET 2015; 6(22): 19132-19147.
________________________________________
Platonova N., Manzo T., Mirandola L., Colombo M. , Calzavara E., Vigolo E., Cermisoni G.C., De Simone D., Garavelli S., Cecchinato V., Lazzari E., Neri A., Chiaramonte R.
PI3K/AKT signaling inhibits NOTCH1 lysosome-mediated degradation.
GENE CHROMOSOME CANC 2015; 54(8): 516-526.
________________________________________
Cifola I., Lionetti M., Pinatel E., Todoerti K., Mangano E., Pietrelli A., Fabris S., Mosca L., Simeon V., Petrucci M.T., Morabito F., Offidani M., Di Raimondo F., Falcone A., Caravita T., Battaglia C. , De Bellis G., Palumbo A., Musto P., Neri A.
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.
ONCOTARGET 2015; 6(19): 17543-17558.
________________________________________
Morelli E., Leone E., Cantafio M.E., Di Martino M.T., Amodio N., Biamonte L., Gulla A., Foresta U., Pitari M.R., Botta C., Rossi M., Neri A., Munshi N.C., Anderson K.C., Tagliaferri P., Tassone P.
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.
LEUKEMIA 2015; 29(): 2173-2183.
________________________________________
Segalla S., Pivetti S., Todoerti K., Chudzik M.A., Giuliani E.C., Lazzaro F., Volta V., Lazarevic D., Musco G., Muzi-Falconi M., Neri A., Biffo S., Tonon G.
The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA.
NUCLEIC ACIDS RES 2015; 43(10): 5182-5193.
________________________________________
Oliva E.N., Lauseker M., Aloe Spiriti M.A., Poloni A., Cortelezzi A., Palumbo G.A., Balleari E., Sanpaolo G., Volpe A., Ricco A., Ronco F., Alati C., D’Errigo M.G., Santacaterina I., Kundgen A., Germing U., Latagliata R.
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
CANCER MED-US 2015; 4(12): 1789-1797.
________________________________________
Iurlo A., Orsi E., Cattaneo D., Resi V., Bucelli C., Orofino N., *Sciumè M., Elena C., Grancini V., Consonni D., Orlandi E.M., Cortelezzi A.
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
ONCOTARGET 2015; 6(32): 33944-33951.
________________________________________
Laurenti L., Innocenti I., Autore F., Vannata B., Efremov D.G., Ciolli S., Del Poeta G., Mauro F.R., Cortelezzi A., Borza P.A., Ghio F., Mondello P., Murru R., Gozzetti A., Cariccio M.R., Piccirillo N., Boncompagni R., Cantonetti M., Principe M.I., Reda G., Bongarzoni V., Cervetti G., Pitini V., Foà R., Sica S., D’Arena G.
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.
LEUKEMIA RES 2015; 39(10): 1066-1070.
________________________________________
Rossi D., Terzi di Bergamo L., De Paoli L., Cerri M., Ghilardi G., Chiarenza A., Bulian P., Visco C., Mauro F.R., Morabito F., Cortelezzi A., Zaja F., Forconi F., Laurenti L., Del Giudice I., Gentile M., Vincelli I., Motta M., Coscia M., Rigolin G.M., Tedeschi A., Neri A., Marasca R., Perbellini O., Moreno C., Del Poeta G., Massaia M., Zinzani P.L., Montillo M., Cuneo A., Gattei V., Foà R., Gaidano G.
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
BLOOD 2015; 126(16): 1921-1924.
________________________________________
Annaloro C., Costa A., Fracchiolla N., Mometto G., Artuso S., Saporiti G., Tagliaferri E., Grifoni F., Onida F., Cortelezzi A.
RIVISTA SENZA I.F. (Clin Case Rep) – Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report.
** 2015; 3(7): 650-655.
________________________________________
Zaninoni A., Vercellati C., Imperiali F., Marcello A., Fattizzo B., Fermo E., Bianchi P., Grossi C., Cattaneo A., Cortelezzi A., Zanella A., Barcellini W.
Detection of red blood cell antibodies in mitogen-stimulated cultures from patients with hereditary spherocytosis.
TRANSFUSION 2015; 55(12): 2930-2938.
________________________________________
*Sciumè M., Vincenti D., Reda G., Orofino N., Cassin R., Giannarelli D., Gaidano G., Rossi D., Cortelezzi A.
Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.
AM J HEMATOL 2015; 90(11): 970-974.
________________________________________
Castagnetti F. , Gugliotta G., Breccia M., Stagno F., Iurlo A., Albano F., Abruzzese E., Martino B., Levato L., Intermesoli T., Pregno P., Rossi G., Gherlinzoni F., Leoni P., Cavazzini F., Venturi C., Soverini S., Testoni N., Alimena G., Cavo M., Martinelli G., Pane F. , Saglio G., Rosti G., Baccarani M., GIMEMA CML W.
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
LEUKEMIA 2015; 29(9): 1823-1831.
________________________________________
Fattizzo B., Zaninoni A., Consonni D., Zanella A., Gianelli U., Cortelezzi A., Barcellini W.
Is chronic neutropenia always a benign disease? Evidences from a 5-year prospective study.
EUR J INTERN MED 2015; 26(8): 611-615.
________________________________________
Morabito F., Cutrona G., Mosca L., D’Anca M., Matis S., Gentile M., Vigna E., Colombo M. , Recchia A.G., Bossio S., De Stefano L., Maura F., Manzoni M., Ilariucci F., Consoli U., Vincelli I., Musolino C., Cortelezzi A., Molica S., Ferrarini M., Neri A.
Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
LEUKEMIA RES 2015; 39(8): 840-845.
________________________________________
Maura F., Cutrona G., Mosca L., Matis S., Lionetti M., Fabris S., Agnelli L., Colombo M. , Massucco C., Ferracin M., Zagatti B., Reverberi D. , Gentile M., Recchia A.G., Bossio S., Rossi D., Gaidano G., Molica S., Cortelezzi A., Di Raimondo F., Negrini M., Tassone P., Morabito F., Ferrarini M., Neri A.
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia.
LEUK LYMPHOMA 2015; 56(11): 3150-3158.
________________________________________
Gianelli U., Iurlo A., Cattaneo D., Bossi A., Cortinovis I., Augello C., Moro A., Savi F., Castelli R., Brambilla C., Bianchi P., Primignani M. , Cortelezzi A., Bosari S.
Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
LEUKEMIA RES 2015; 39(5): 525-529.
________________________________________
Maura F., Mosca L., Fabris S., Cutrona G., Matis S., Lionetti M., Agnelli L., Barbieri M., D’Anca M., Manzoni M., Colombo M. , Massucco C., Reverberi D. , Gentile M., Recchia A.G., Bossio S., Ilariucci F., Musolino C., Di Raimondo F., Cortelezzi A., Morabito F., Ferrarini M., Neri A.
Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia.
PLOS ONE 2015; 10(3): e0118801-e0118801.
________________________________________
Bassan R., Masciulli A., Intermesoli T., Audisio E., Rossi G., Pogliani EM., Cassibba V., Mattei D., Romani C., Cortelezzi A., Corti C. , Scattolin A.M., Spinelli O., Tosi M., Parolini M., Marmont F., Borlenghi E., Fumagalli M., Cortelazzo S., Gallamini A., Marfisi R.M., Oldani E., Rambaldi A.
Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
HAEMATOL-HEMATOL J 2015; 100(6): 786-793.
________________________________________
Tarella C., Arcaini L., Baldini L., Barosi G., Billio A., Marchetti M., Rambaldi A., Vitolo U., Zinzani P.L., Tura S.
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphoc
CL LYMPH MYELOM LEUK 2015; 15(2): 75-85.
________________________________________
Castagnetti F. , Gugliotta G., Baccarani M., Breccia M., Specchia G., Levato L., Abruzzese E., Rossi G., Iurlo A., Martino B., Pregno P., Stagno F., Cuneo A., Bonifacio M., Gobbi M., Russo D., Gozzini A., Tiribelli M. , de Vivo A., Alimena G., Cavo M., Martinelli G., Pane F. , Saglio G., Rosti G.
Differences among young adults, adults and elderly chronic myeloid leukemia patients.
ANN ONCOL 2015; 26(1): 185-192.
________________________________________
Augello C., Gianelli U., Falcone R., Tabano S., Savi F., Bonaparte E., Ciboddo M., Paganini L., Parafioriti A., Ricca D., Lonati S., Cattaneo D., Fracchiolla N., Iurlo A., Cortelezzi A., Bosari S., Miozzo M., Sirchia S.M.
PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis.
LEUKEMIA RES 2015; 39(2): 236-241.
________________________________________
Burger J.A., Tedeschi A., Barr P.M., Robak T., Owen C., Ghia P., Bairey O., Hillmen P., Bartlett N.L., Li J., Simpson D., Grosicki S., Devereux S., McCarthy H., Coutre S., Quach H., Gaidano G., Maslyak Z., Stevens D.A., Janssens A., Offner F., Mayer J., O’Dwyer M., Hellmann A., Schuh A., Siddiqi T., Polliack A., Tam C.S., Suri D., Cheng M., Clow F., Styles L., James D.F., Kipps T.J., RESONATE-2 I., Cortelezzi A.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
NEW ENGL J MED 2015; 373(25): 2425-2437.
________________________________________
Girmenia C., Rossolini G.M., Piciocchi A., Bertaina A., Pisapia G., Pastore D., Sica S., Severino A., Cudillo L., Ciceri F., Scimè R., Lombardini L., Viscoli C., Rambaldi A., Gruppo Italiano Trapianto di Midollo Osseo G., Mometto G., Annaloro C.
Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy.
BONE MARROW TRANSPL 2015; 50(2): 282-288.
________________________________________
Bernardi M., Zappasodi P., Fracchiolla N., Marbello L., Todisco E., Pagani C., Carrabba M., Rossi M., *Guidotti F., Mancini V., Santoro A., Borlenghi E., Ciceri F., Morra E., Rossi G.
Post-remission intensive treatment after induction chemotherapy is feasible in selected elderly patients with acute myeloid leukemia and age =75 years: a retrospective analysis of the Rete Ematologica Lombarda.
AM J HEMATOL 2015; 90(6): E123-E125.
________________________________________
Musto P., Fraticelli V.L., Mansueto G., Madonna E., Nozza A., Andriani A., Mussetti A., Ballanti S., Bongarzoni V., Baraldi A., Patriarca F., Vincelli D., Falcone A., Derudas D. , Califano C., Zambello R., Mele G., Fragasso A., Baldini L., Storti S.
Bendamustine in relapsed/refractory multiple myeloma: the “real-life” side of the moon.
LEUK LYMPHOMA 2015; 56(5): 1510-1513.
________________________________________
Mangiacavalli S. , Pochintesta L., Ravelli E., Baldini L., Ferretti V.V., La Targia M.L., Farina L., Cocito F., Cairoli R., Montefusco E., Corso A.
Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.
LEUK LYMPHOMA 2015; 56(6): 1901-1902.
________________________________________
Tedeschi A., Rossi D., Motta M., Quaresmini G., Rossi M., Coscia M., Anastasia A., Rossini F., Cortelezzi A., Nador G., Scarfò L., Cairoli R., Frustaci A.M., Dalceggio D., Picardi P., De Paoli L., Orlandi E., Rambaldi A., Massaia M., Gaidano G., Montillo M.
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.
HAEMATOL-HEMATOL J 2015; 100(12): e501-e504.
________________________________________
Iurlo A., Cattaneo D., Boiocchi L., Orofino N., Fermo E., Cortelezzi A., Gianelli U.
Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib.
ANN HEMATOL 2015; 94(10): 1749-1751.
________________________________________
Fattizzo B., Zaninoni A., Nesa F., Sciumbata V.M., Zanella A., Cortelezzi A., Barcellini W.
Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias.
AM J HEMATOL 2015; 90(8): E149-E151.
________________________________________
Iurlo A., Cattaneo D., Giunta M., Gianelli U., Consonni D., Fraquelli M., Orofino N., Bucelli C., Bianchi P., Augello C., Bosari S., Colombo M. , Cortelezzi A.
Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre.
BRIT J HAEMATOL 2015; 170(6): 890-892.
________________________________________
Piva R., Deaglio S., Famà R., Buonincontri R., Scarfò L., Bruscaggin A., Mereu E., Serra S., Spina V., Brusa D., Monti S., Dal Bo M., Marasca R., Arcaini L., Neri A., Gattei V., Paulli M., Tiacci E., Bertoni F., Pileri SA., Foà R., Inghirami G., Gaidano G., Rossi D.
The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma.
LEUKEMIA 2015; 29(2): 503-507.
________________________________________
Iurlo A., Cattaneo D., Gianelli U., Fermo E., Augello C., Cortelezzi A.
Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis.
ANN HEMATOL 2015; 94(5): 881-882.
________________________________________
Morabito F., Cutrona G., Gentile M., Fabris S., Matis S., Vigna E., Todoerti K., Colombi M., Recchia A.G., Bossio S., De Stefano L., Ilariucci F., Cortelezzi A., Consoli U., Vincelli I., Pesce E.A., Musolino C., Molica S., Di Raimondo F., Neri A., Ferrarini M.
Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study.
BRIT J HAEMATOL 2015; 168(3): 455 -459.
________________________________________
